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Objective: Alkaptonuria (AKU) is a rare genetic disease which results in severe early onset osteo-
arthropathy. It has recently been shown that the subchondral interface is of key signiﬁcance in disease
pathogenesis. Human surgical tissues are often beyond this initial stage and there is no published murine
model of pathogenesis, to study the natural history of the disease. The murine genotype exists but it has
been reported not to demonstrate ochronotic osteoarthropathy consistent with the human disease.
Recent anecdotal evidence of macroscopic renal ochronosis in a mouse model of tyrosinaemia led us to
perform histological analysis of tissues of these mice that are known to be affected in human AKU.
Design: The homogentisate 1,2-dioxygenase Hgdþ/Fah/ mouse can model either hereditary tyrosi-
naemia type I (HT1) or AKU depending on selection conditions. Mice having undergone Hgd reversion
were sacriﬁced at various time points, and their tissues taken for histological analysis. Sections were
stained with haematoxylin eosin (H&E) and Schmorl’s reagent.
Results: Early time point observations at 8 months showed no sign of macroscopic ochronosis of tissues.
Macroscopic examination at 13 months revealed ochronosis of the kidneys. Microscopic analysis of the
kidneys revealed large pigmented nodules displaying distinct ochre colouration. Close microscopic
examination of the distal femur and proximal ﬁbula at the subchondral junctions revealed the presence
of numerous pigmented chondrocytes.
Conclusions: Here we present the ﬁrst data showing ochronosis of tissues in a murine model of AKU.
These preliminary histological observations provide a stimulus for further studies into the natural history
of the disease to provide a greater understanding of this class of arthropathy.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Alkaptonuria (AKU) is a rare autosomal recessive condition that
is caused by a single enzyme deﬁciency in the tyrosine metabolic
pathway1. The absent enzyme is homogentisate 1,2-dioxygenase
(HGD), which is responsible for the conversion of homogentisic
acid (HGA) to 4-maleylacetoacetic acid (MAA)2. Enzyme loss results
in accumulation of HGA in both tissues and circulating blood1. HGA
shows a particularly high afﬁnity for collagenous tissues; initial
deposits are associated with the periodicity of collagen ﬁbres3.
Between the third and fourth decade of life, accumulation of HGA
polymers begins to manifest in joint disorders, culminating in.M. Taylor, Lancaster Medical
versity, C16, Faraday Building,
503.
r).
s Research Society International. Pdevastating arthropathy. Furthermore, HGA-associated pigment
known as ochronosis has detrimental effects on other collagenous
matrices in the body4,5. Ochronosis of cartilage was recently shown
to be initiated in individual chondrocytes and their territorial
matrix, before progressing to a more widespread pigmentation of
the cartilage matrix6. Elucidation of the mechanism by which
ochronosis begins and progresses will provide new targets for
intervention. It has been suggested that 2-[2-nitro-4-(tri-
ﬂuoromethyl)benzoyl]cyclohexane-1,3-dione (NTBC), the thera-
peutic agent used in treating a related tyrosine catabolic disorder
hereditary tyrosinaemia type I (HT1), may prove beneﬁcial in
treating AKU by blocking the production of HGA in the breakdown
of tyrosine7 (Fig. 1). The efﬁcacy and safety associated with the use
of this drug to treat AKU has yet to be determined, but testing
would be facilitated by access to a mouse model of joint pathology.
A murine model of AKU was generated in 1994 by ENU-induced
mutagenesis8. The AKU mutation was then backcrossed onto bothublished by Elsevier Ltd. All rights reserved.
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Fig. 1. Diagram of the phenylalanine and tyrosine metabolic pathway highlighting
enzymes and associated defects. A¼ Tyrosinemia type II, B¼ Tyrosinemia type III,
C¼ AKU, D¼ Tyrosinemia type I. NTBC is shown at its site of action.
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previously thought not to exhibit ochronosis, despite excreting
sufﬁcient HGA to cause darkening of urine9. The mice have trun-
cated HGD protein resulting from a splice mutation8.
The related tyrosine disorder HT1 is caused by a deﬁciency of
(Fah) e the terminal enzyme in the pathway e that causes
progressive liver disease and renal tubular dysfunction10. In both
HT1 patients and Fah/ mice, toxic metabolites like fumar-
ylacetoacetate (FAA) accumulate causing death in a cell-
autonomous manner. Treatment with NTBC, an inhibitor that
blocks upstream of FAH, prevents metabolite accumulation and
rescues the phenotype11. Hgd/ and FAA hydrolase (Fah) deﬁcient
mice have been crossed for several generations to produce
Hgd/Fah/ mice12. Interestingly, some mice with the interme-
diate genotype Hgdþ/Fah/, were resistant to liver failure char-
acteristic of HT1 when withdrawn from NTBC. Histological
examination showed healthy liver nodules in these mice, suggest-
ing reversion had occurred at the Hgd locus. The reversion is
thought to arise as a response to the production of reactive
compounds in the liver and kidneys, namely FAA, and other
subsequent spontaneously formed derivatives. Individual hepato-
cytes that revert to the double knockout genotype have a selective
advantage within the liver as they do not produce the toxic deriv-
atives12. The accumulation of such hepatotoxic compounds can be
prevented by NTBC administration. Hgdþ/Fah/ neonates must
nurse from a mother on NTBC as neonates are acutely sensitive to
HT1-related hepatotoxin accumulation during this developmental
window and will die from acute liver failure within 24 h without
NTBC from the breast milk. However, when Hgdþ/Fah/ adult
mice are withdrawn from NTBC, a small percentage will undergo
a loss of heterozygosity (LOH) event at the Hgd locus generating an
Hgd/Fah/ hepatocyte that is resistant to effects of the FAH
deﬁciency. These reverted hepatocytes now have a selective
advantage and can clonally expand to repopulate the liver. As
a consequence, the block to HGD leads to an accumulation of HGA
in the liver and blood stream.
Other models of ochronosis have been reported, but are gener-
ally not useful or viable for experimental studies13,14. Following
anecdotal descriptions of ochronosis in Hgdþ/Fah/ mice with-
drawn from NTBC, we undertook both a macro- and microscopic
study of their tissues. Here we describe the ﬁrst detection of
ochronosis in a murine model of AKU and similarities between theinitial stages of pigmentation in the murine model and those of the
human condition. We expect that this murine model will prove
beneﬁcial for screening therapeutic agents for treating the
condition.
Materials and methods
Mouse strains and animal husbandry
Hgd/ and Fah/ mice were bred to generate Hgdþ/Fah/
mice. The Hgd mutation was generated by an ENU-mutagenesis
screen8, while the Fah mutation was generated by neo-cassette
insertion into exon 515. The resultant Hgdþ/Fah/ can model
either HT1 or AKU depending on selection conditions from the
time spent off NTBC. Hgdþ/Fah/ neonates will die from acute
HT1erelated liver failure if NTBC is not continually administered.
NTBC treatment at 4-mg/L in the drinking water prevents hep-
atorenal injury and rescues the phenotype. Short-term NTBC
withdrawal allows modelling of HT1 as mice rapidly develop hep-
atorenal disease over the course of several weeks and die of end-
stage liver disease in 6e8 weeks10. Long-term NTBC withdrawal
can stimulate LOH at the Hgd locus resulting in mice with an
Hgd/Fah/ genotype. These mice model AKU and are protected
from HT1-related damage from the upstream Hgd mutation9.
Depending on the selection conditions desired, mice were main-
tained on either 4-mg/L NTBC in the drinking water or water with
no added drug, and fed irradiated high-fat low-proteinmouse chow
(Lab Diet Cat#Picolab 5LJ5) ad libitum to decrease ﬂux through the
tyrosine pathway. The Institutional Animal Care and Use
Committee of Oregon Health & Science University approved all
procedures and mouse experiments.
Histology
Hgdþ/ Fah/ mice having undergone Hgd reversion were
sacriﬁced at various time points; one mouse (male) at 8 months
and six mice (four males and two females) at 13 months, and their
tissues taken for analysis. Kidneys were sectioned through the
midline, dividing into an anterior and posterior half prior to pro-
cessing. Tissue samples were washed in phosphate buffer saline
(PBS) and then ﬁxed in 10% phosphate buffered formol saline
(PBFS). Mineralized tissues were decalciﬁed with 12% ethyl-
enediaminetetraacetic acid (EDTA) in 10% formalin. Following
ﬁxation and/or decalciﬁcation, tissues were routinely processed for
histology and parafﬁn embedded. Five-micrometre sections were
cut andmounted on glass slides, knees were sectioned transversely
from lateral to medial. Sections were stained with either haema-
toxylin eosin (H&E) (every third section) or Schmorl’s reagent
(every fourth section) which we have previously shown to be
a sensitive stain for tissue ochronosis16. Stained sections were
dehydrated and mounted in Dibutyl phthalate in Xylene (DPX)
(Sigma, UK).
Results
Macroscopic ﬁndings
Early time point observations of survivors at 8 months off NTBC
showed no sign of macroscopically visible ochronosis to the skin,
eyes, ears, femur, knee joint, vertebrae or various cartilages. An
examination of the liver showed a mosaic pattern of nodules of
relatively normal tissue among areas of damage. Histological
analysis of early time point animals was not undertaken.
Interestingly, macroscopic examination of the liver at 13 months
off NTBC revealed yellow-brown discolouration with signs of
Fig. 2. Macroscopic image of large ochronotic renal nodules from an Hgd/Fah/
(reverted from Hgdþ/ Fah/) mouse harvested after 13 months off NTBC. Dark
deposits can be seen on both kidneys. Note the pale discolouration of the surrounding
non-ochronotic renal tissues.
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the retroperitoneal structures revealed large nodules on both
kidneys (Fig. 2). These nodules were black, indicative of ochronosis.
In the regions of the kidneys not affected by ochronosis, necrosis
and inﬂammation were observed. Following kidney dissection,
macroscopic observations showed pigmented nodules in the renal
columns, cortices and medulla. There were no grossly visible signs
of ochronosis in the skin, ears, adipose tissue in the abdominal
cavity, digestive tract, vertebral column, weight-bearing joints orFig. 3. Near serial kidney sections from an Hgd/Fah/ (reverted from Hgdþ/ Fah/) mou
formed in the distended tubules by H&E. Pigmentation is seen both within the nodule itself a
derivative in these structures and the cells within is visible by Schmorl’s stain. Field widthother large cartilages at 13 months. Additionally, tendons inserting
into the large joints, as well as heart and aortic vasculature revealed
no signs macroscopically of brown colouring that would imply
ochronotic pigmentation.
Microscopic ﬁndings
Renal system
Microscopic analysis of the kidneys revealed a large inﬂamma-
tory reaction across the organ. Large pigmented nodules within the
kidneys displayed distinct ochre colouration (Fig. 3A). Within and
surrounding these nodules were abundant mononuclear cells, all of
which showed dense intracellular pigmentation in their cytoplasm.
Within these cells was uniform ochronotic pigmentation along
with some easily identiﬁable dense crystals. Schmorl’s staining of
near serial sections conﬁrmed the presence of ochronotic
pigmentation within the cells (Fig. 3B).
A cross section of the renal tubules showed the presence of both
pigmented urine and crystals within collecting ducts, distal, prox-
imal and thin tubules by H&E (Fig. 4A, C). Glomeruli lacked signs of
ochronosis. Schmorl’s staining of near serial sections of these areas
conﬁrmed the presence of ochronosis within these structures
(Fig. 4B). Interestingly Schmorl’s staining also identiﬁed early
pigmentation in some of the epithelial cells in distal tubules, not
identiﬁed by H&E. Within these tubules, mononuclear cells with
pigmented cytoplasm could also be seen.
Examination of the renal extracellular matrix showed no
evidence of ochronosis by H&E. However, when near serial sections
were stained with Schmorl’s reagent, low levels of early pigmen-
tation were detected in and peripheral to the regions where the
densely pigmented nodules were found (Fig. 4D).
Musculoskeletal system
Low power microscopic examination of the knee joints revealed
normal bone and cartilage architecture with no evidence of dense
ochronotic pigmentation of the articular cartilage matrix at any ofse harvested after 13 months off NTBC. (A) Dense ochronosis can be seen in the nodules
nd lining the periphery. (B) Conﬁrmation of HGA presence and its polymeric ochronotic
s 0.84 mm.
Fig. 4. Near serial sections showing the presence of polymerized HGA urine in the tubules of the kidneys from Hgd/Fah/ (reverted from Hgdþ/ Fah/) mice. (A) Presence of
numerous ochronotic deposits across the kidney by H&E. (B) Schmorl’s staining conﬁrming the presence of ochronotic deposits within the tubules. (C) Intra-tubular and intracellular
deposition (arrow) within the cells by H&E. (D) Schmorl’s staining conﬁrming the presence of ochronotic pigmentation within the tubules and intracellular deposits. Many smaller
deposits associated with the surrounding cells and possibly the collagenous matrices are present (arrow). (Field widths: A & B 1.2 mm, C & D 0.3 mm).
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at the subchondral junction revealed the presence of numerous
pigmented chondrocytes (Fig. 5). In many cases, these cells were
necrotic or dead; they occupied a smaller fraction of their lacunae
than their non-ochronotic neighbouring cells. It was also difﬁcult to
distinguish nucleus from cytoplasm in the ochronotic cells. They
displayed dense granular pigmentation intracellularly and more
uniform pigmentation of the territorial matrix. Numerous groups ofFig. 5. Histological section showing the overview of a knee joint from an Hgd/Fah/
(reverted from Hgdþ/ Fah/) mouse. No obvious signs of ochronosis are present in
the cartilages of the knee joint. F¼ Femur, M¼Meniscus, T¼ Tibia, Fi¼ Fibula. Inset:
initial ochronosis associated with the pericellular matrix of the deep chondrocytes
(arrows). Intracellular deposits can also be seen. Note the absence of pigmentation
from the interterritorial matrix and bone matrix (Field width 3 mm).chondrocytes with pericellular pigmentation were observed in
close proximity. In the interterritorial matrix between these pig-
mented groups, there was no extracellular pigmentation associated
with the cartilage matrix. There were also numerous chondrocytes
in these regions that showed intracellular pigmentation without
the pericellular pigmentation (Fig. 5 inset). The majority of the
latter chondrocytes were still alive, with a clearly identiﬁable
nucleus. Superﬁcial to these were chondrocytes that displayed
intracellular and faint pericellular pigmentation. At the articular
surface, no sign of pigmentation was visible, either intra- or extra-
cellularly. Deep to these chondrocytes, the bone was examined for
the presence of ochronotic pigmentation, however no comparable
pigmentation was seen within the calciﬁed matrix, nor in the
osteocytes, osteoblasts or osteoclasts examined.
Similar histological examination was undertaken in the prox-
imal tibia and ﬁbula, alongside the distal femur. Ochronotic
pigment was seen both intracellularly and pericellularly (Fig. 6A).
The osteocytes located in the bone beneath these pigmented cells
were free of pigmentation (Fig. 6B). In articular regions, there was
identical presentation of ochronotic pigmentation in the deep
chondrocytes, as well as intra- and pericellular pigmentation of the
more superﬁcial chondrocytes. There was no form of pigmentation
at the articular surface. The entheses inserting into the bones of the
knee joint were also examined, but displayed no sign of ochronosis.
These same regions were then examined using Schmorl’s reagent.
Schmorl’s stain highlighted the presence of early pigment associ-
ated with the chondrocytes in the ﬁbrocartilaginous insertion of
the entheses (Fig. 6C), which was not detected by H&E. Dense
pigmentationwas associated with the deep chondrocytes and their
pericellular matrix. It also showed the presence of pigment in and
around the more superﬁcial chondrocytes (Fig. 6D). Interestingly,
this staining also conﬁrmed the absence of pigmentation from the
Fig. 6. Near serial sections showing ochronosis in the distal femur and ﬁbula of Hgd/Fah/ (reverted from Hgdþ/ Fah/) mice by H&E and Schmorl’s. (A) Ochronosis can be seen
in the pericellular and territorial matrices of individual chondrocytes in the deep layer of both the femur and ﬁbula (H&E). (B) Ochronosis in the pericellular and territorial matrices
of individual chondrocytes in the deep layer of the distal femur (H&E). Note the absence of pigmentation at the superﬁcial and articular surfaces. (C) Near serial section of (A)
showing the distal femur and ﬁbular head stained with Schmorl’s to identify ochronosis around and within chondrocytes, including those in the superﬁcial layer of the distal femur.
(D) Near serial section of (B) showing the distal femur stained with Schmorl’s reagent. Pigmentation is identiﬁed intracellularly and within the pericellular and territorial matrices of
chondrocytes of the deep layer, but also seen more readily in the superﬁcial zone with both intracellular and pericellular deposits identiﬁable (Field width 0.3 mm).
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of the mineralized bone matrices or any of the bone cells was seen.
Examination of the shoulder by H&E at low power demon-
strated an interesting presentation of ochronosis in a small number
of chondrocytes at varied locations. Even greater numbers of cells
demonstrating early pigmentation could be seen when near serial
sections were stained with Schmorl’s than by H&E. These stained
chondrocytes were most notable in the columns of chondrocytes
located within the entheses. There were fewer stained chon-
drocytes peripheral to these columns, those that were stained in
these peripheral regions were stained to a lesser intensity. The
staining was most prominent in intracellular and pericellular
regions, while little staining could be seen in the interterritorial
matrices. Through utilization of both H&E and Schmorl’s stain, it
was concluded that no pigmentation was present in the chon-
drocytes of the articular surface across the shoulder joint. The
epiphyseal plate showed dense proteoglycan staining, but all cells
and extracellular matrix were devoid of pigmentation when
examined using both stains.
Analysis of the thoracic and lumbar vertebrae revealed an
absence of pigmentation both intra- and extra-cellularly when
observed by H&E. Analysis of the vertebral articulations with
Schmorl’s reagent revealed a small number of chondrocytes with
intracellular and pericellular pigmentation when viewed in
sections. The spinal cord also displayed no ochronosis when
analyzed using either stain.
Cardiovascular and respiratory system
Microscopic examination of the laryngeal cartilages revealed
dense proteoglycan staining in the thyroid cartilage matrix and
numerous chondrocytes appeared necrotic/apoptotic, but theydemonstrated no detectable sign of ochronosis. The muscular
insertions onto the laryngeal cartilages displayed no sign of
ochronosis. Examination of the tracheal ring cartilages, tracheal
epithelia, and ﬁbrous tissues showed no ochronotic pigmentation.
Microscopic examination of the heart revealed dense muscular
tissue with no sign of ochronosis. Examination of the heart valves
and their attachment to the muscular tissue displayed normal
connective tissues and no sign of intracellular or extracellular
ochronosis. Analysis of the ascending and descending aorta
revealed no signs of ochronosis associated with any layer of the
vessel architecture. There was no sign of cellular ochronosis in the
tissues.Discussion
Here we present the ﬁrst data showing ochronosis of tissues in
a murine model of AKU. It has previously been published that mice
with AKU exist, however these animals have not previously been
reported to display the usual phenotypic ochronosis seen in the
adult human, even though they have elevated levels of urinary
HGA8,17. Several hypothesis have been suggested to explain the
discrepancy including that the endogenous production of ascorbic
acid is a protective mechanism against the gradual ochronosis of
tissues in these animals18, that these mousemodels do not live long
enough to allow deposition to occur in their tissues, or that urinary
excretion is so complete that tissues do not experience high enough
concentrations of HGA. Here we show that tissues, including those
of the joints, show ochronosis in mice carrying the mutation for the
disease, when combined with the effects of a second mutation in
Fah.
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may be protective for these mice. Our results show that mere
presence of ascorbic acid is not sufﬁcient to completely prevent
pigmentation in all mice. While mice that have been alkaptonuric
from birth have not yet been shown to display pigmentation,
longitudinal studies covering the whole of their lifespan do not
exist, so it is difﬁcult to completely rule out pigmentation in aged
specimens. It has also been suggested that HGA is not the sole
determining factor in pigmentation3. The non-uniform distribution
of pigmentation in Hgd/Fah/ (reverted from Hgdþ/ Fah/)
mice supports this idea as neither these mice nor regions of these
mice show pigmentation in the ﬁrst 8 months following the initial
reversion to the AKU phenotype many months before sampling.
Detection of pigmentationwithin the kidneys in these animals is
not surprising from a functional point of view as this is the site of
blood ﬁltration and high metabolic activity. It is well documented
that the darkening of urine is a sign of ochronosis and that renal
manifestations in humans are not uncommon. For example, docu-
mented cases of passing pigmented kidney stones, pigmentation
within human kidneys, and histologically-associated manifesta-
tions of renal deposition have been described4,19.
The kidneys in these animals are of interest as the effects of
NTBC withdrawal and FAA accumulation may seriously affect their
ability to function. The loss of function may also be similar to the
renal decline experienced by human AKU patients with ageing,
limiting the ability of the kidneys to excrete HGA20. However, there
is currently no longitudinal data detailing the urinary and plasma
levels of HGA in AKU patients prior to known ochronosis, or the
change over time once pigmentation starts. Observations made in
adolescence that can then be compared following removal of
a known ochronotic joint or repeated measurement of ochronosis
in the sclera or pinna are needed.
It is widely accepted that there is HGA present in the urine of the
Hgd/ and Hgd/Fah/mice. Whilst data exists detailing urinary
HGA concentrations in these mice17, there is currently no published
data describing the concentration of the HGA in the plasma of these
animals. Despite this, we show that regardless of the concentration
of HGA in these animals, levels are sufﬁcient to initiate polymeri-
zation and deposition of ochronotic pigment in multiple tissues.
Absence of deposition in the cardiac connective tissues is not
surprising, given that not all AKU patients present with cardiac
involvement, suggesting that lifestyle factors may play a role in the
deposition process. Whatever these factors may be, they are yet to
be elucidated.
It has recently been shown that deposition in the human
condition starts focally, associated with single chondrocytes in the
calciﬁed cartilage, progressing towards the articular surface with
intracellular deposition appearing to precede the extracellular
deposition6. It appears that the initiation in these animals is the
same, demonstrating that these animals may be valuable for
screening therapeutic strategies for inhibiting or reversing pigment
deposition in AKU. Whilst bone changes are seen in the human
disorder6, they were not observed in these mice: bone matrix and
bone cells were devoid of pigmentation. This also adds weight to
the hypothesis that mineralization is protective in the disorder. We
hold that bone changes are secondary to the cartilage pathology in
the progression of AKU, so while bone changes were not observed
in these animals, they may occur at a later stage, once the carti-
laginous changes become more widespread.
The observations within the chondrocytes of two distinctly
different types of pigmentation (granular and uniform) are inter-
esting, as this suggests that similar to the human condition,
pigmentation may actually arise under two different mechanisms
within these tissues5. This adds further weight to our claim of
synonymy with the human condition. Murine models have proveduseful for investigation into disorders on the tyrosine metabolic
pathway, particularly with the AKU mouse model which was
inﬂuential in decoding the location of the then unknown human
mutation8,21,22. The proposed treatment of AKU using NTBC came
about from investigations into mice deﬁcient in Fah. These animals
are exposed to the build up of toxic tyrosinemetabolites neonatally,
once FAH production begins around day 16 of foetal development.
Untreated Fah/ mice do not survive beyond 24 h of birth;
however administration of NTBC to mothers whilst pregnant
results in the neonatal effect of FAH deﬁciency being abolished11.
NTBC for treatment of HT1 is now widely used, although it is not
without some risks. Treated patients are still vulnerable to other
dermatologic, ophthalmologic and neurodevelopmental compli-
cations associated with elevated blood tyrosine levels9. In addition,
paediatric patients who go undiagnosed and are without NTBC
treatment for greater than 6 months are at high risk of developing
hepatocarcinoma12. Fah/ and Hgdþ/Fah/ mice show general
health deterioration following withdrawal from NTBC. In contrast,
Hgd/Fah/ mice are healthy at 4, 7, 9 and 11 weeks off NTBC12.
Localised reversion from Hgdþ/ to Hgd/ in liver cells can take
place spontaneously during the crisis invoked by withdrawal of
Hgdþ/Fah/ mice from NTBC. A similar phenotype and sponta-
neous mutation has also been described in Aspergillus23. The
reversion to the AKU phenotype in this model system showed the
distinct darkening of culture media23. Furthermore, it has been
shown that kidneys from Fah/ mice off NTBC are pale and
enlarged, conﬁrming that they are abnormal10. This may result
from an increase in the stresses to the kidneys, which in turn
promotes ochronosis in the surrounding renal regions.
It is encouraging that the earliest signs of pigmentation in these
animals have been observed and that they are synonymous with
those in the human condition. It is within this critical time that
ochronosis would need to be treated in human AKU, to prevent full
ochronotic osteoarthropathy from developing. Based on our pub-
lished evidence and that described in the literature, it is unlikely
that deposition of pigment can be reversed6. This time point in the
murine model will act as a useful tool for screening potential
therapeutic agents. Detection of ochronosis in murine tissues
represents a signiﬁcant advance in the knowledge and under-
standing of alkaptonuric osteoarthropathy and will allow us to gain
a better understanding into the molecular pathogenesis of the
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